Trial Profile
PHASE II CLINICAL TRIAL OF MEK 1/2 INHIBITOR AZD6244 IN CANCERS WITH BRAF MUTATIONS IDENTIFIED BY PROSPECTIVE GENOTYPIC ANALYSIS (NCI 8281)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary)
- Indications Colon cancer; Non-small cell lung cancer; Solid tumours
- Focus Therapeutic Use
- 23 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Jun 2015 Planned End Date changed from 1 Jun 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
- 28 Jun 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov record.